<DOC>
	<DOCNO>NCT01874249</DOCNO>
	<brief_summary>The purpose randomize clinical trial evaluate utility noninvasive marker detection advance fibrosis patient newly diagnose Non-alcoholic Fatty Liver Disease ( NAFLD ) ultrasound . The primary objective determine effectiveness noninvasive marker detect advanced fibrosis patient diagnosis fatty liver disease . The secondary objective : - To determine increase health care specialist ( gastroenterologist endocrinologist ) . - To determine noninvasive evaluation strategy favor treatment fatty liver disease .</brief_summary>
	<brief_title>Non Invasive Assessment Liver Fibrosis Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Patients BMI â‰¥ 27 Kg/m2 stage non alcoholic fatty liver , diagnose ultrasound . Patients liver disease . Patients treatment tamoxifen , methotrexate , amiodarone , diltiazem drug able induce fatty liver . Patients alcohol consumption great 140 gr . per week Patients receive blood transfusion 1990</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hepatic fibrosis</keyword>
	<keyword>Steatosis</keyword>
	<keyword>Noninvasive marker .</keyword>
</DOC>